ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 831,23
1,54%
DAX
18 518,03
-0,44%
Brent Oil
83,355
-1,17%
Bitcoin
64 282,00
-0,88%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
15/08/200714h00PR Newswire (US)Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/08/200715h00PR Newswire (US)Allos Therapeutics Reports Second Quarter 2007 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
18/07/200714h00PR Newswire (US)Allos Therapeutics to Report 2007 Second Quarter Financial Results on August 7, 2007NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/06/200715h30PR Newswire (US)Allos Therapeutics Selected to Join Russel 3000 IndexNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/06/200712h30PR Newswire (US)Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From BreastNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/05/200723h01PR Newswire (US)Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's DiseasNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/05/200723h55PR Newswire (US)Allos Therapeutics Files Shelf Registration StatementNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/05/200714h30PR Newswire (US)Allos Therapeutics Reports First Quarter 2007 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/05/200719h21PR Newswire (US)Allos Therapeutics to Announce 2007 First Quarter Results on Tuesday, May 8NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/04/200714h00PR Newswire (US)Allos Therapeutics Appoints Dr. Jeffrey R. Latts to Its Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/04/200714h30PR Newswire (US)Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European CommissionNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/03/200713h00PR Newswire (US)Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical OfficerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/03/200713h00PR Newswire (US)Allos Therapeutics Reports Fourth Quarter and 2006 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
27/02/200714h00PR Newswire (US)Allos Therapeutics to Report 2006 Fourth Quarter Financial Results on Monday, March 5NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/02/200714h00PR Newswire (US)Allos Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/02/200717h01PR Newswire (US)Allos Therapeutics Announces Closing of Common Stock OfferingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/01/200712h00PR Newswire (US)Allos Therapeutics Announces Pricing of Underwritten Offering of 9,000,000 Shares of Common StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200721h19PR Newswire (US)Allos Therapeutics to Present at the 2007 JP Morgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200713h05PR Newswire (US)Allos Therapeutics Appoints William R. Ringo to Its Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200713h00PR Newswire (US)Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in PatienNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/12/200617h46PR Newswire (US)Results Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics' Novel AnNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/11/200614h00PR Newswire (US)Allos Therapeutics Added to NASDAQ Biotech IndexNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/11/200614h15PR Newswire (US)Updated Safety Analysis of Allos Therapeutics Phase 1/2 Study of PDX in Patients With Aggressive Lymphomas Demonstrates DecreaseNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/11/200619h56PR Newswire (US)Allos Therapeutics Announces Presentation of Updated Results From Phase 1/2 Trial of PDX in Patients With Aggressive Lymphomas aNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/11/200618h00PR Newswire (US)Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential ChemorNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/11/200613h30PR Newswire (US)Allos Therapeutics Reports Third Quarter 2006 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/11/200622h00PR Newswire (US)Allos Therapeutics to Announce 2006 Third Quarter Financial Results on Friday, November 3NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/10/200618h30PR Newswire (US)Allos Therapeutics Announces Presentations on EFAPROXYN(TM) and PDX at Upcoming Scientific ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/10/200613h29PR Newswire (US)Allos Therapeutics Announces ENRICH Trial UpdateNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/10/200615h00PR Newswire (US)Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

NYSE
MCD
McDonalds
NASDAQ
MSFT
Microsoft
EU
AI
Air Liquide
NASDAQ
AMZN
Amazon.com
SPI
SP500
S&P 500
EU
CS
Axa
EU
PX1
CAC 40
EU
AF
Air FranceKLM
NYSE
DIS
Walt Disney
EU
BNP
BNP Paribas
NYSE
KO
Coca Cola
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés